Role of dendritic cell metabolic reprogramming in tumor immune evasion
Abstract The dendritic cell (DC) is recognized as a vital mediator of anti-tumor immunity. More recent studies have also demonstrated the important role of DCs in the generation of effective responses to checkpoint inhibitor immunotherapy. Metabolic programming of DCs dictates their functionality an...
Gespeichert in:
| Veröffentlicht in: | International immunology 2020-06, Vol.32 (7), p.485-491 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 491 |
|---|---|
| container_issue | 7 |
| container_start_page | 485 |
| container_title | International immunology |
| container_volume | 32 |
| creator | Plebanek, Michael P Sturdivant, Michael DeVito, Nicholas C Hanks, Brent A |
| description | Abstract
The dendritic cell (DC) is recognized as a vital mediator of anti-tumor immunity. More recent studies have also demonstrated the important role of DCs in the generation of effective responses to checkpoint inhibitor immunotherapy. Metabolic programming of DCs dictates their functionality and can determine which DCs become immunostimulatory versus those that develop a tolerized phenotype capable of actively suppressing effector T-cell responses to cancers. As a result, there is great interest in understanding what mechanisms have evolved in cancers to alter these metabolic pathways, thereby allowing for their continued progression and metastasis. The therapeutic strategies developed to reverse these processes of DC tolerization in the tumor microenvironment represent promising candidates for future testing in combination immunotherapy clinical trials. |
| doi_str_mv | 10.1093/intimm/dxaa036 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7318778</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><oup_id>10.1093/intimm/dxaa036</oup_id><sourcerecordid>2406575153</sourcerecordid><originalsourceid>FETCH-LOGICAL-c448t-3dcd9bac250ba4262466f95aaefb47c26d1ced78f936dd8f776d4c9988d9f17f3</originalsourceid><addsrcrecordid>eNqFkE1LAzEQhoMotlavHmWPemib3WSTzUWQYlUoCKLnkM1HjWySmuwW_fduaS315GlmmGfemXkBuMzhJIcMTa1vrXNT9SUEROQIDHNM4LhAlB4f5ANwltIHhBAVDJ2CASowZpSSIZi_hEZnwWRKexVta2UmddNkTreiDk1fRr2KYRmFc9YvM-uztnMhZv3WzutMr0WywZ-DEyOapC92cQTe5vevs8fx4vnhaXa3GEuMq3aMlFSsFrIoYS1wQQpMiGGlENrUmMqCqFxqRSvDEFGqMv2JCkvGqkoxk1ODRuB2q7vqaqeV1L6NouGraJ2I3zwIy_92vH3ny7DmFOUVpVUvcL0TiOGz06nlzqbNx8Lr0CVeYEhKWuYl6tHJFpUxpBS12a_JId-Yz7fm8535_cDV4XF7_NftHrjZAqFb_Sf2A1nEk48</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2406575153</pqid></control><display><type>article</type><title>Role of dendritic cell metabolic reprogramming in tumor immune evasion</title><source>MEDLINE</source><source>Oxford University Press Journals All Titles (1996-Current)</source><source>EZB-FREE-00999 freely available EZB journals</source><source>Alma/SFX Local Collection</source><creator>Plebanek, Michael P ; Sturdivant, Michael ; DeVito, Nicholas C ; Hanks, Brent A</creator><creatorcontrib>Plebanek, Michael P ; Sturdivant, Michael ; DeVito, Nicholas C ; Hanks, Brent A</creatorcontrib><description>Abstract
The dendritic cell (DC) is recognized as a vital mediator of anti-tumor immunity. More recent studies have also demonstrated the important role of DCs in the generation of effective responses to checkpoint inhibitor immunotherapy. Metabolic programming of DCs dictates their functionality and can determine which DCs become immunostimulatory versus those that develop a tolerized phenotype capable of actively suppressing effector T-cell responses to cancers. As a result, there is great interest in understanding what mechanisms have evolved in cancers to alter these metabolic pathways, thereby allowing for their continued progression and metastasis. The therapeutic strategies developed to reverse these processes of DC tolerization in the tumor microenvironment represent promising candidates for future testing in combination immunotherapy clinical trials.</description><identifier>ISSN: 1460-2377</identifier><identifier>ISSN: 0953-8178</identifier><identifier>EISSN: 1460-2377</identifier><identifier>DOI: 10.1093/intimm/dxaa036</identifier><identifier>PMID: 32449776</identifier><language>eng</language><publisher>UK: Oxford University Press</publisher><subject>Animals ; Dendritic Cells - immunology ; Dendritic Cells - metabolism ; Humans ; Immunotherapy ; Invited Reviews ; Neoplasms - immunology ; Neoplasms - therapy ; Tumor Microenvironment - immunology</subject><ispartof>International immunology, 2020-06, Vol.32 (7), p.485-491</ispartof><rights>The Japanese Society for Immunology. 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2020</rights><rights>The Japanese Society for Immunology. 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.</rights><rights>The Author(s) 2020. Published by Oxford University Press on behalf of The Japanese Society for Immunology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2020</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c448t-3dcd9bac250ba4262466f95aaefb47c26d1ced78f936dd8f776d4c9988d9f17f3</citedby><cites>FETCH-LOGICAL-c448t-3dcd9bac250ba4262466f95aaefb47c26d1ced78f936dd8f776d4c9988d9f17f3</cites><orcidid>0000-0002-2803-3272</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,777,781,882,1579,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32449776$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Plebanek, Michael P</creatorcontrib><creatorcontrib>Sturdivant, Michael</creatorcontrib><creatorcontrib>DeVito, Nicholas C</creatorcontrib><creatorcontrib>Hanks, Brent A</creatorcontrib><title>Role of dendritic cell metabolic reprogramming in tumor immune evasion</title><title>International immunology</title><addtitle>Int Immunol</addtitle><description>Abstract
The dendritic cell (DC) is recognized as a vital mediator of anti-tumor immunity. More recent studies have also demonstrated the important role of DCs in the generation of effective responses to checkpoint inhibitor immunotherapy. Metabolic programming of DCs dictates their functionality and can determine which DCs become immunostimulatory versus those that develop a tolerized phenotype capable of actively suppressing effector T-cell responses to cancers. As a result, there is great interest in understanding what mechanisms have evolved in cancers to alter these metabolic pathways, thereby allowing for their continued progression and metastasis. The therapeutic strategies developed to reverse these processes of DC tolerization in the tumor microenvironment represent promising candidates for future testing in combination immunotherapy clinical trials.</description><subject>Animals</subject><subject>Dendritic Cells - immunology</subject><subject>Dendritic Cells - metabolism</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Invited Reviews</subject><subject>Neoplasms - immunology</subject><subject>Neoplasms - therapy</subject><subject>Tumor Microenvironment - immunology</subject><issn>1460-2377</issn><issn>0953-8178</issn><issn>1460-2377</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1LAzEQhoMotlavHmWPemib3WSTzUWQYlUoCKLnkM1HjWySmuwW_fduaS315GlmmGfemXkBuMzhJIcMTa1vrXNT9SUEROQIDHNM4LhAlB4f5ANwltIHhBAVDJ2CASowZpSSIZi_hEZnwWRKexVta2UmddNkTreiDk1fRr2KYRmFc9YvM-uztnMhZv3WzutMr0WywZ-DEyOapC92cQTe5vevs8fx4vnhaXa3GEuMq3aMlFSsFrIoYS1wQQpMiGGlENrUmMqCqFxqRSvDEFGqMv2JCkvGqkoxk1ODRuB2q7vqaqeV1L6NouGraJ2I3zwIy_92vH3ny7DmFOUVpVUvcL0TiOGz06nlzqbNx8Lr0CVeYEhKWuYl6tHJFpUxpBS12a_JId-Yz7fm8535_cDV4XF7_NftHrjZAqFb_Sf2A1nEk48</recordid><startdate>20200626</startdate><enddate>20200626</enddate><creator>Plebanek, Michael P</creator><creator>Sturdivant, Michael</creator><creator>DeVito, Nicholas C</creator><creator>Hanks, Brent A</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2803-3272</orcidid></search><sort><creationdate>20200626</creationdate><title>Role of dendritic cell metabolic reprogramming in tumor immune evasion</title><author>Plebanek, Michael P ; Sturdivant, Michael ; DeVito, Nicholas C ; Hanks, Brent A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c448t-3dcd9bac250ba4262466f95aaefb47c26d1ced78f936dd8f776d4c9988d9f17f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>Dendritic Cells - immunology</topic><topic>Dendritic Cells - metabolism</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Invited Reviews</topic><topic>Neoplasms - immunology</topic><topic>Neoplasms - therapy</topic><topic>Tumor Microenvironment - immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Plebanek, Michael P</creatorcontrib><creatorcontrib>Sturdivant, Michael</creatorcontrib><creatorcontrib>DeVito, Nicholas C</creatorcontrib><creatorcontrib>Hanks, Brent A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Plebanek, Michael P</au><au>Sturdivant, Michael</au><au>DeVito, Nicholas C</au><au>Hanks, Brent A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Role of dendritic cell metabolic reprogramming in tumor immune evasion</atitle><jtitle>International immunology</jtitle><addtitle>Int Immunol</addtitle><date>2020-06-26</date><risdate>2020</risdate><volume>32</volume><issue>7</issue><spage>485</spage><epage>491</epage><pages>485-491</pages><issn>1460-2377</issn><issn>0953-8178</issn><eissn>1460-2377</eissn><abstract>Abstract
The dendritic cell (DC) is recognized as a vital mediator of anti-tumor immunity. More recent studies have also demonstrated the important role of DCs in the generation of effective responses to checkpoint inhibitor immunotherapy. Metabolic programming of DCs dictates their functionality and can determine which DCs become immunostimulatory versus those that develop a tolerized phenotype capable of actively suppressing effector T-cell responses to cancers. As a result, there is great interest in understanding what mechanisms have evolved in cancers to alter these metabolic pathways, thereby allowing for their continued progression and metastasis. The therapeutic strategies developed to reverse these processes of DC tolerization in the tumor microenvironment represent promising candidates for future testing in combination immunotherapy clinical trials.</abstract><cop>UK</cop><pub>Oxford University Press</pub><pmid>32449776</pmid><doi>10.1093/intimm/dxaa036</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0002-2803-3272</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1460-2377 |
| ispartof | International immunology, 2020-06, Vol.32 (7), p.485-491 |
| issn | 1460-2377 0953-8178 1460-2377 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7318778 |
| source | MEDLINE; Oxford University Press Journals All Titles (1996-Current); EZB-FREE-00999 freely available EZB journals; Alma/SFX Local Collection |
| subjects | Animals Dendritic Cells - immunology Dendritic Cells - metabolism Humans Immunotherapy Invited Reviews Neoplasms - immunology Neoplasms - therapy Tumor Microenvironment - immunology |
| title | Role of dendritic cell metabolic reprogramming in tumor immune evasion |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T08%3A06%3A41IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Role%20of%20dendritic%20cell%20metabolic%20reprogramming%20in%20tumor%20immune%20evasion&rft.jtitle=International%20immunology&rft.au=Plebanek,%20Michael%20P&rft.date=2020-06-26&rft.volume=32&rft.issue=7&rft.spage=485&rft.epage=491&rft.pages=485-491&rft.issn=1460-2377&rft.eissn=1460-2377&rft_id=info:doi/10.1093/intimm/dxaa036&rft_dat=%3Cproquest_pubme%3E2406575153%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2406575153&rft_id=info:pmid/32449776&rft_oup_id=10.1093/intimm/dxaa036&rfr_iscdi=true |